These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 27592701)

  • 1. Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications.
    Yoshihara M; Hayashizaki Y; Murakawa Y
    Stem Cell Rev Rep; 2017 Feb; 13(1):7-16. PubMed ID: 27592701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Instability of iPSCs and Challenges in Their Clinical Applications.
    Yoshihara M; Oguchi A; Murakawa Y
    Adv Exp Med Biol; 2019; 1201():23-47. PubMed ID: 31898780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor-induced Reprogramming and Zinc Finger Nuclease-aided Gene Targeting Cause Different Genome Instability in β-Thalassemia Induced Pluripotent Stem Cells (iPSCs).
    Ma N; Shan Y; Liao B; Kong G; Wang C; Huang K; Zhang H; Cai X; Chen S; Pei D; Chen N; Pan G
    J Biol Chem; 2015 May; 290(19):12079-89. PubMed ID: 25795783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs).
    Singh VK; Kumar N; Kalsan M; Saini A; Chandra R
    J Stem Cells; 2015; 10(1):43-62. PubMed ID: 26665937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redox and Epigenetics in Human Pluripotent Stem Cells Differentiation.
    Giallongo S; Rehakova D; Raffaele M; Lo Re O; Koutna I; Vinciguerra M
    Antioxid Redox Signal; 2021 Feb; 34(4):335-349. PubMed ID: 32567336
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of Integrating and Non-Integrating Reprogramming Methods on Copy Number Variation and Genomic Stability of Human Induced Pluripotent Stem Cells.
    Kang X; Yu Q; Huang Y; Song B; Chen Y; Gao X; He W; Sun X; Fan Y
    PLoS One; 2015; 10(7):e0131128. PubMed ID: 26131765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic stability during cellular reprogramming: Mission impossible?
    von Joest M; Búa Aguín S; Li H
    Mutat Res; 2016 Jun; 788():12-6. PubMed ID: 26851988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming.
    Rony IK; Baten A; Bloomfield JA; Islam ME; Billah MM; Islam KD
    Cell Prolif; 2015 Apr; 48(2):140-56. PubMed ID: 25643745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications.
    Liu G; David BT; Trawczynski M; Fessler RG
    Stem Cell Rev Rep; 2020 Feb; 16(1):3-32. PubMed ID: 31760627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental approaches for the generation of induced pluripotent stem cells.
    Sommer CA; Mostoslavsky G
    Stem Cell Res Ther; 2010 Aug; 1(3):26. PubMed ID: 20699015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the risks of genotoxicity in the therapeutic development of induced pluripotent stem cells.
    Hong SG; Dunbar CE; Winkler T
    Mol Ther; 2013 Feb; 21(2):272-81. PubMed ID: 23207694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Messenger RNA- versus retrovirus-based induced pluripotent stem cell reprogramming strategies: analysis of genomic integrity.
    Steichen C; Luce E; Maluenda J; Tosca L; Moreno-Gimeno I; Desterke C; Dianat N; Goulinet-Mainot S; Awan-Toor S; Burks D; Marie J; Weber A; Tachdjian G; Melki J; Dubart-Kupperschmitt A
    Stem Cells Transl Med; 2014 Jun; 3(6):686-91. PubMed ID: 24736403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antioxidant supplementation reduces genomic aberrations in human induced pluripotent stem cells.
    Ji J; Sharma V; Qi S; Guarch ME; Zhao P; Luo Z; Fan W; Wang Y; Mbabaali F; Neculai D; Esteban MA; McPherson JD; Batada NN
    Stem Cell Reports; 2014 Jan; 2(1):44-51. PubMed ID: 24511469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Insight into Reprogramming Barriers to iPSC Generation.
    Haridhasapavalan KK; Raina K; Dey C; Adhikari P; Thummer RP
    Stem Cell Rev Rep; 2020 Feb; 16(1):56-81. PubMed ID: 31758374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
    Qi SD; Smith PD; Choong PF
    ANZ J Surg; 2014 Jun; 84(6):417-23. PubMed ID: 24894037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steps toward safe cell therapy using induced pluripotent stem cells.
    Okano H; Nakamura M; Yoshida K; Okada Y; Tsuji O; Nori S; Ikeda E; Yamanaka S; Miura K
    Circ Res; 2013 Feb; 112(3):523-33. PubMed ID: 23371901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
    Qi SD; Smith PD; Choong PF
    ANZ J Surg; 2014 Jun; 84(6):E1-11. PubMed ID: 23035845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reprogramming mechanism and genetic stability of induced pluripotent stem cells (iPSCs)].
    Ren C; Sun H; Wang L; Zhang G; Fan Y; Yan G; Wang D; Wang F
    Yi Chuan; 2014 Sep; 36(9):879-87. PubMed ID: 25252305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Obstacles to Clinical Translation of iPSCs.
    Tapia N; Schöler HR
    Cell Stem Cell; 2016 Sep; 19(3):298-309. PubMed ID: 27452174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.